Alnylam Pharmaceuticals Inc
Research Alnylam Pharmaceuticals Inc (ALNY) on Bullrun: valuation model: 13.3% overvalued, market cap USD 32.11B, P/E 40.5. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALNY
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal13.3% overvalued
- Market capUSD 32.11B
- P/E40.5
- Financial periodQ2 2026
- RevenueUSD 1.29B
- Net incomeUSD 164.49M
- Free cash flowUSD 292.04M
- Gross margin76.9%
Valuation Snapshot
Bullrun's latest valuation model marks Alnylam Pharmaceuticals Inc as 13.3% overvalued; latest market cap is USD 32.11B; P/E is 40.5.
Peer valuation comparison
Latest P/E is 40.53x versus a Healthcare sector median of 24.46x (65.7% above).
Latest P/E is 40.53x versus a United States median of 24.87x (63.0% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.71B | USD 313.75M | USD 465.38M | 81.8% | 2.33 | USD 1.66B | USD 1.28B | USD 789.18M |
| FY2024 | USD 2.25B | -USD 278.16M | -USD 42.59M | 86.4% | -2.18 | USD 966.43M | USD 1.30B | USD 67.09M |
| FY2023 | USD 1.83B | -USD 440.24M | USD 41.95M | 85.3% | -3.52 | USD 812.69M | USD 1.31B | -USD 220.64M |
| FY2022 | USD 1.04B | -USD 1.13B | -USD 613.33M | 86.5% | -9.3 | USD 866.39M | USD 990.98M | -USD 158.22M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 32.11B | 40.5 | n/a | n/a |
| 2025 | 2025-12-31 | USD 52.64B | 176.0 | n/a | n/a |
| 2024 | 2024-12-31 | USD 30.42B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 24.02B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 29.24B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 20.38B | n/a | n/a | n/a |
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Alnylam Pharmaceuticals Inc overvalued or undervalued?
Bullrun's valuation model currently marks Alnylam Pharmaceuticals Inc as 13.3% overvalued.
What is Alnylam Pharmaceuticals Inc's market cap?
Alnylam Pharmaceuticals Inc's market capitalization is USD 32.11B.
What is Alnylam Pharmaceuticals Inc's P/E ratio?
Alnylam Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 40.5.
What does Alnylam Pharmaceuticals Inc do?
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.